Accelagen is thrilled to welcome Mathew Palmer as our new Chief Growth & Commercial Officer (CGCO). With an exceptional track record spanning nearly 30 years in the life sciences industry, Mathew’s experience and leadership will be invaluable as we continue to expand and enhance our services. In this post, we’ll introduce Mathew, highlight his professional journey, and discuss what his appointment means for the future of Accelagen.
Mathew’s Rich Career in Life Sciences
Mathew Palmer’s career in the life sciences industry is nothing short of impressive. Starting out in the clinical research associate (CRA) space, Mathew quickly expanded his expertise to project management, team leadership, and business development. Over the years, he honed his skills at both small and large CROs (Contract Research Organizations), as well as global pharmaceutical giants such as AstraZeneca, Sanofi (formerly Aventis), and Novartis.
At Trident, a mid-sized Australian CRO, Mathew was tasked with creating and leading their study startup group. As the company grew through the acquisition of Trident by INC Research, his leadership in this area led to his promotion to Project Director, where he managed early-phase studies in Australia and New Zealand. Mathew’s transition to business development came as a natural progression, allowing him to combine his deep technical knowledge with his passion for driving growth and building strong client relationships.
Mathew has also held numerous advisory and industry roles with both government and industry and is the current branch chair in South Australia for AusBiotech.
What Drew Mathew to Accelagen?
Mathew’s decision to join Accelagen was influenced by several key factors. As he mentions, he has always thrived in innovative, more agile organizations, where close-knit teams can collaborate effectively to drive growth. Having spent much of his career in CROs, he recognized Accelagen as a company with a strong reputation for quality and a commitment to delivering excellent clinical services to customers.
One of the aspects that stood out to Mathew was Accelagen’s ability to offer full-service capabilities in Australia, ensuring clients can get the complete package of services without needing to outsource to multiple vendors or regions. This capability, along with the company’s focus on regulatory and clinical development quality, aligns perfectly with Mathew’s background and vision for growth.
What to Expect in 2025 and Beyond
As Accelagen enters a new chapter with Mathew on board, we can expect several exciting developments in the near future. Mathew’s role will be central to driving continued company expansion, focusing not only on regional growth but also on enhancing efficiencies and customer satisfaction.
One of Mathew’s core priorities will be expanding Accelagen’s international footprint and offering more tailored solutions for customers. He aims to build on the strong foundation already in place and leverage his extensive operational and business development experience to help clients navigate the increasingly complex landscape of clinical trials.
“We’re going to focus on building lasting partnerships with our customers,” Mathew emphasizes. “It’s not about being a vendor. We want to be a trusted partner, supporting our clients through every stage of the clinical development process.”
Key Themes for the Future
Mathew has a clear vision for the future of Accelagen, one that revolves around delivering exceptional value and building a customer-centric culture.
– Quality & Delivery: Mathew is committed to ensuring that Accelagen continues to deliver on time and within budget, with a strong focus on quality at every stage of the clinical process.
– Customer-Centric Approach: As he puts it, honesty and transparency will be core to Accelagen’s operations. Clients can expect a team that is always open and responsive, ready to help them move assets to patients more efficiently and effectively.
– Collaborative Leadership: Mathew sees Accelagen as a company where senior leadership is available for our customers and where cross-functional teams collaborate seamlessly to meet client needs. The leadership team supports key decisions and committed to creating an environment that is both dynamic and supportive, ensuring the company remains agile and able to respond to the needs of the industry.
Looking Ahead to a Big Year
As Accelagen heads into 2025, Mathew is excited about the journey ahead. He’s looking forward to working with the team to not only meet but exceed expectations, and to continue the strong momentum the company has built over the past year. “There are many challenges in the industry, but we’re all very committed to achieving our goals, and those of our customers,” he shares.
Mathew’s leadership comes at a pivotal time for Accelagen as we look to strengthen our position in the global clinical trial services market. His blend of deep industry knowledge, operational expertise, and passion for growth makes him the perfect fit to lead Accelagen into the next phase of its development.
Join Us in Welcoming Mathew to Accelegen Mathew and the Accelagen team attended the 43rd JP Morgan Healthcare Conference and the 2025 Biotech Showcase in San Francisco and met with many companies looking to further develop their treatments for patients. He is still available for virtual partnering. Schedule a time to meet with us using the Bio PartneringONE system, directly via linked in or at [email protected].
We are excited to see how Mathew’s leadership will drive Accelagen’s growth and help us continue providing world-class services to our clients. His dedication to quality, customer satisfaction, and business expansion will undoubtedly have a lasting impact on the company’s success.
About Accelagen:
Accelagen is an Australian-based company specialising in regulatory affairs, clinical research and product development services. With a strong focus on early-phase studies and cell therapy trials, Accelagen works with researchers and organisations to bring innovative therapies to market. Through their deep expertise in clinical trial management, regulatory affairs, and data analysis, Accelagen plays a critical role in helping local researchers navigate the complex journey from the lab to the clinic.
Contact Information: For more information about the spinal cord injury clinical trial please contact Griffith University at [email protected]. To enquire about Accelagen’s services and how we can support your clinical development needs, please visit our website.